Corcept (CORT) Faces Class Action Lawsuit Over FDA Data Misstatements
On April 7, 2026, Hagens Berman Sobol Shapiro LLP, a national law firm specializing in shareholder rights, announced a critical deadline for investors in Corcept Therapeutics Incorporated (NASDAQ: CORT). Those who purchased shares between October 31, 2024, and December 30, 2025, are encouraged to seek appointment as Lead Plaintiff in a pending securities class action. The lawsuit, filed in the U.S. District Court for the Northern District of California, aims to recover losses incurred by stakeholders during this period.
The legal action, titled "Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al.," centers on allegations that the company made materially false and misleading statements regarding its lead drug candidate, relacorilant. Investors are particularly focused on claims that Corcept deliberately concealed information about its communications with the FDA, which reportedly raised serious concerns about the effectiveness of the clinical data supporting the New Drug Application (NDA).
The core of this lawsuit revolves around a so-called 'information gap' between the public statements made by Corcept and internal warnings issued by the FDA. According to leading attorney Reed Kathrein, who is overseeing the firm’s investigation, pre-submission meeting notes from 2024 and early 2025 indicated that the FDA had advised Corcept on multiple occasions that the clinical data lacked the necessary evidence to support a successful NDA. Despite these warnings, Corcept continued to promote optimistic narratives about the outcome of its Phase 3 clinical trials, suggesting that the data was solid and in line with regulatory expectations.
The situation escalated dramatically on December 31, 2025, when Corcept disclosed that it received a Complete Response Letter (CRL) from the FDA. The agency stated that it could not consider relacorilant favorably due to an insufficient evidentiary basis for its effectiveness. Following this announcement, Corcept’s stock price suffered a staggering collapse, dropping from $70.20 per share to $34.80 within a single day, effectively erasing approximately $2.5 billion in market capitalization.
The implications of this case extend beyond just financial losses. Investors who feel deceived by Corcept’s practices are now rallying to ensure that their voices are heard in court. The deadline to apply for Lead Plaintiff status is set for April 21, 2026, which compels affected investors to act quickly. Hagens Berman encourages those impacted to visit their dedicated CORT Case Page for more information regarding the lawsuit and related allegations.
Additionally, Hagens Berman is advising whistleblowers with non-public information concerning the case to come forward. The SEC Whistleblower program offers incentives, including potential rewards of up to 30% of any recovery obtained by the SEC based on new information provided by whistleblowers.
As this unfolding legal saga illustrates, transparency and accountability in the pharmaceutical world are paramount. Corcept investors are urged to stay informed about their rights and the ongoing developments related to this litigation. The firm, which has a rich history of advocating for investor rights and securing significant settlements for its clients, remains committed to achieving justice for those impacted by Corcept’s actions. For further details about the case or to share your experiences, reach out to the firm directly. Investors can also follow updates via the firm’s official social media platforms, including @ClassActionLaw.
The legal action, titled "Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al.," centers on allegations that the company made materially false and misleading statements regarding its lead drug candidate, relacorilant. Investors are particularly focused on claims that Corcept deliberately concealed information about its communications with the FDA, which reportedly raised serious concerns about the effectiveness of the clinical data supporting the New Drug Application (NDA).
Background on Corcept and the Allegations
The core of this lawsuit revolves around a so-called 'information gap' between the public statements made by Corcept and internal warnings issued by the FDA. According to leading attorney Reed Kathrein, who is overseeing the firm’s investigation, pre-submission meeting notes from 2024 and early 2025 indicated that the FDA had advised Corcept on multiple occasions that the clinical data lacked the necessary evidence to support a successful NDA. Despite these warnings, Corcept continued to promote optimistic narratives about the outcome of its Phase 3 clinical trials, suggesting that the data was solid and in line with regulatory expectations.
The situation escalated dramatically on December 31, 2025, when Corcept disclosed that it received a Complete Response Letter (CRL) from the FDA. The agency stated that it could not consider relacorilant favorably due to an insufficient evidentiary basis for its effectiveness. Following this announcement, Corcept’s stock price suffered a staggering collapse, dropping from $70.20 per share to $34.80 within a single day, effectively erasing approximately $2.5 billion in market capitalization.
The Class Action Implications
The implications of this case extend beyond just financial losses. Investors who feel deceived by Corcept’s practices are now rallying to ensure that their voices are heard in court. The deadline to apply for Lead Plaintiff status is set for April 21, 2026, which compels affected investors to act quickly. Hagens Berman encourages those impacted to visit their dedicated CORT Case Page for more information regarding the lawsuit and related allegations.
Additionally, Hagens Berman is advising whistleblowers with non-public information concerning the case to come forward. The SEC Whistleblower program offers incentives, including potential rewards of up to 30% of any recovery obtained by the SEC based on new information provided by whistleblowers.
Conclusion
As this unfolding legal saga illustrates, transparency and accountability in the pharmaceutical world are paramount. Corcept investors are urged to stay informed about their rights and the ongoing developments related to this litigation. The firm, which has a rich history of advocating for investor rights and securing significant settlements for its clients, remains committed to achieving justice for those impacted by Corcept’s actions. For further details about the case or to share your experiences, reach out to the firm directly. Investors can also follow updates via the firm’s official social media platforms, including @ClassActionLaw.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.